1. bookTom 132 (2022): Zeszyt 1 (January 2022)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2083-4829
Pierwsze wydanie
23 Apr 2014
Częstotliwość wydawania
1 raz w roku
Języki
Angielski
Otwarty dostęp

Gut microbiome in non-alcoholic fatty liver disease

Data publikacji: 20 Jul 2022
Tom & Zeszyt: Tom 132 (2022) - Zeszyt 1 (January 2022)
Zakres stron: 11 - 15
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2083-4829
Pierwsze wydanie
23 Apr 2014
Częstotliwość wydawania
1 raz w roku
Języki
Angielski

1. Flint HJ. The impact of nutrition on the human microbiome. Nutr Rev. 2012;70(1):10-13. Search in Google Scholar

2. Grice EA, Segre JA. The human microbiome: „Our second genome”. Annu Rev Genomics Hum Genet. 2012;13:151-70. Search in Google Scholar

3. Dominguez-Bello MG, Costello E, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. PNAS. 2010;107(26):11971-5. Search in Google Scholar

4. Zhu X, Han Y, Du J, et al. Microbiota-gut-brain axis and the central nervous system. Oncotarget. 2017;8(32):53829-38. Search in Google Scholar

5. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. Search in Google Scholar

6. Eslam M, Newsome PN, Sarin SK, et al. A new definitione for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9. Search in Google Scholar

7. Found Y, Waked I, Bollipo S, et al. What’s in a name? Renaming NAFLD to MAFLD. Liver Int. 2020;40:1254-61. Search in Google Scholar

8. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877-87. Search in Google Scholar

9. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50(5):585-8. Search in Google Scholar

10. Zuwala-Jagiello J, Pazgan-Simon M, Simon K, et al. Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis. J Physiol Pharmacol. 2019;70(3):399-405. Search in Google Scholar

11. Yan-Lan F, Hong C, Chun-Lin W, Li L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol. 2018;24(27):2974-83. Search in Google Scholar

12. Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: From fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol. 2014;20(27):9038-49. Search in Google Scholar

13. Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: Pathophysiology and Management. Gastroenterol Clin North Am. 2016;45(4):639-52. Search in Google Scholar

14. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197-211. Search in Google Scholar

15. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5. Search in Google Scholar

16. Wawrzynowicz-Syczewska M, Waszczyk A, Bander D, et al. PNPLA3 gene polymorphism and severity of liver steatosis and fibrosis. Arch Med Scie Civil Dis. 2021;6:31-5. Search in Google Scholar

17. Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6):1. Search in Google Scholar

18. Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol. 2015;7(3):575-82. Search in Google Scholar

19. Gottlieb A, Canbay A. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression. Cells. 2019;8(11):1358. Search in Google Scholar

20. Olsen I, Yamazaki K. Can oral bacteria affect the microbiome of the gut? Sci Rep. 2015;5:8096. Search in Google Scholar

21. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. Peer J. 2019;7:7502. Search in Google Scholar

22. Redondo-Useros N, Nova E, González-Zancada N, Diaz LE, Gómez-Martinez S, Marcos A. Microbiota and lifestyle: A special focus on diet. Nutrients. 2020;12(6):1776. Search in Google Scholar

23. Magne F, Gotteland M, Gauthier L, et al. The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? Nutrients. 2020;12(5):1474. Search in Google Scholar

24. Konturek PC, Harsch IA, Konturek K, et al. Gut-liver axis: How do gut bacteria influence the liver? Med Sci (Basel). 2018;6(3):79. Search in Google Scholar

25. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regu-lates fat storage. Proc Natl Acad Sci USA. 2004;101:15718-23. Search in Google Scholar

26. Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007;104:979-84. Search in Google Scholar

27. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;21(7122): 1027-31. Search in Google Scholar

28. Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787-94. Search in Google Scholar

29. Wang B, Jiang X, Cao M, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. sci rep. 2016;6:32002. Search in Google Scholar

30. Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015; 91(2):1-9. Search in Google Scholar

31. Zhu L, Baker SS, Gill C, et al. Characterisation of gut microbiomes in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-9. Search in Google Scholar

32. Boursier J, Mueller O, Barret M, et al. The severity of non-alcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-75. Search in Google Scholar

33. Xu R, Tao A, Zhang S, et al. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8:3924-34. Search in Google Scholar

34. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011-9. Search in Google Scholar

35. Szulińska M, Loniewski I, van Hemert S, et al. Dose-dependent effects of multispecies probiotic supplementation on the Lipopolysaccharide (LPS) level and cardiometabolic profile in obese postmenopausal women: A 12-week randomized clinical trial. Nutrients. 2018;15:10. Search in Google Scholar

36. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343-50. Search in Google Scholar

37. Seliverstov PS, Stanislav V, Radchenko LB, et al. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with non-alcoholic fatty liver disease, thus preventing the progression of the disease. Eksp Klin Gastroenterol. 2018;4:4-18. Search in Google Scholar

38. Nabavi S, Rafraf M, Somi MH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014;97(12):7386-7393. Search in Google Scholar

39. Wegh CA, Geerlings SY, Knol J, et al. Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci. 2019;20(19):4673. Search in Google Scholar

40. Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics-A step beyond pre- and probiotics. Nutrients. 2020;12(8):2189. Search in Google Scholar

41. Rose S, Nyiazov DM, Rossignol DA, et al. Clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder. Mol Diagn Ther. 2018;22(5):571-93. Search in Google Scholar

42. Fuentes M, Lajo T, Carrión J, Cuñé J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. BJN. 2013;109(10):1866-72. Search in Google Scholar

43. Abdel-Razik A, Mousa N, Shabana W, et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018;30(10):1237-46. Search in Google Scholar

44. Wijarnpreecha K, Lou S, Watthanasuntorn K, et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(5):601-8. Search in Google Scholar

45. Kuang L, Zhou W, Jiang Y. Association of small intestinal bacterial over-growth with nonalcoholic fatty liver disease in children: A meta-analysis. PLoS One. 2021;16(12):0260479. Search in Google Scholar

46. Okubo H, Nakatsu Y, Sakoda H, et al. Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015;308:151-8. Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo